Ypsomed shares climbed 8.8% to CHF 331.2 after the Swiss maker of injection systems for self-medication released its FY2025/26 full-year results in Zurich and provided forward guidance above analyst expectations. Management presented the numbers on Wednesday, 20 May 2026, and the report beat consensus across the principal metrics market participants follow.
For FY2025/26 the group reported revenue of CHF 731.0 million, outpacing the consensus of CHF 718.0 million. Revenue from the Delivery Systems division came in at CHF 601.5 million versus an expected CHF 592.0 million. Group EBIT reached CHF 246.1 million, topping the CHF 241.0 million consensus figure. The company also issued FY26/27 guidance that was higher than analysts had pencilled in, contributing to the strong market reaction.
The full-year results built on momentum established in the first half of the financial year. In the first half Ypsomed recorded 21% growth in its core Delivery Systems business, with sales of CHF 267.0 million. The company highlighted recently introduced platforms including YpsoDot, YpsoFlow, and YpsoLoop as part of its product mix.
Operational metrics in the report showed resilience in the core business. Ypsomed reported an EBIT margin of 32.4% in its Delivery Systems operations and indicated strong operating cash flow, metrics that underpinned investor confidence in the sustainability of earnings.
Analyst coverage and sentiment entering the print already skewed positive. The average 12-month analyst price target prior to the announcement was CHF 387.82, with 10 analysts rated as buy and none rated as sell.
The equity's advance occurred in spite of weakness across major US equity benchmarks, highlighting the company-specific nature of the move. On the same day the S&P 500 fell 0.7%, the Nasdaq declined 0.8%, and the Dow Jones lost 0.7%, indicating that macro-driven selling pressure did not drive Ypsomed's rally.
Ypsomed operates through segments including Ypsomed Diabetes Care and Ypsomed Delivery Systems, focusing on the development and manufacture of injection systems for self-medication. The stock traded at CHF 331.2 following the release - comfortably above its 52-week low of CHF 260.5 but still below its 52-week high of CHF 441.5. The market move reflects a re-rating of the company’s earnings trajectory following the clean full-year beat, resilient Delivery Systems growth, and above-consensus forward guidance.
Key contextual details:
- Results presentation date: Wednesday, 20 May 2026
- FY2025/26 group revenue: CHF 731.0 million (consensus CHF 718.0 million)
- FY2025/26 Delivery Systems revenue: CHF 601.5 million (consensus CHF 592.0 million)
- FY2025/26 Group EBIT: CHF 246.1 million (consensus CHF 241.0 million)
- First-half Delivery Systems sales: CHF 267.0 million, 21% growth
The results package and higher-than-expected guidance provided a clear catalyst for revaluation, as investors adjusted their expectations for near-term earnings and cash generation. That re-pricing occurred while broader indices were declining, underlining the company-specific drivers behind the share move.